<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0028-3746</journal-id>
<journal-title><![CDATA[Neumología y cirugía de tórax]]></journal-title>
<abbrev-journal-title><![CDATA[Neumol. cir. torax]]></abbrev-journal-title>
<issn>0028-3746</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Neumología y Cirugía de Tórax; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas; Sociedad Cubana de Neumología; Sociedad Paraguaya de Neumología; Sociedad Boliviana de Neumología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0028-37462018000200137</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Perfil mutacional de EGFR en adenocarcinoma pulmonar en pacientes fumadores y no fumadores]]></article-title>
<article-title xml:lang="en"><![CDATA[EGFR mutations in pulmonary adenocarcinoma in smoking and non-smoking patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Ríos]]></surname>
<given-names><![CDATA[Carla Paola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rumbo-Nava]]></surname>
<given-names><![CDATA[Uriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Báez-Saldaña]]></surname>
<given-names><![CDATA[Renata]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivera-Rosales]]></surname>
<given-names><![CDATA[Rosa Ma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luna-Rivero]]></surname>
<given-names><![CDATA[César]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Téllez-Navarrete]]></surname>
<given-names><![CDATA[Norma Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pensado-Piedra]]></surname>
<given-names><![CDATA[Lya]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<volume>77</volume>
<numero>2</numero>
<fpage>137</fpage>
<lpage>144</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0028-37462018000200137&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0028-37462018000200137&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0028-37462018000200137&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  El marcador más usado y confiable para la selección de pacientes candidatos a ser tratados con inhibidores de tirosina quinasa es la detección de mutaciones en los exones 19 al 21 del gen EGFR. El comportamiento de estas mutaciones depende del factor exposicional y esto tiene implicaciones pronósticas.  Objetivo:  Evaluar el perfil epidemiológico de las mutaciones de EGFR en adenocarcinoma pulmonar en pacientes fumadores y no fumadores expuestos a humo de leña en el Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas.  Material y métodos:  Se realizó un estudio observacional, retrospectivo y transversal, en el Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México. Se incluyeron pacientes con diagnóstico de adenocarcinoma pulmonar en el período de junio 2013-diciembre 2016. Se analizaron variables cualitativas (género, ocupación, exposición a biomasa, patrón histológico de adenocarcinoma, grado de diferenciación histológica, estadío clínico, presencia de metástasis, mutación en gen EGFR) y cuantitativas (edad, tabaquismo, exposición a humo de leña). El análisis se realizó en términos de frecuencias absolutas y relativas, así como medidas de tendencia central.  Resultados:  Se analizó una muestra total de 252 pacientes, 58.33% femenino y 41.67% del sexo masculino. Se identificó mutación de EGFR en un 32.5%. Se encontró que el exón mutado con mayor frecuencia en ambos sexos fue el 19 con diferencias en patrón histológico y en relación al factor exposicional.  Conclusión:  La caracterización de perfiles moleculares es una herramienta de suma utilidad en el planteamiento de ofertas terapéuticas en cáncer pulmonar de células no pequeñas. Esto es de interés, pues al igual que el patrón histológico, tiene implicación pronóstica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  The most widely used and reliable marker for the selection of patients candidates for treatment with tyrosine kinase inhibitors is the detection of mutations in exons 19 to 21 of the EGFR gene. The behavior of these mutations depends on the exposure factor and this has prognostic implications.  Objective:  To evaluate the epidemiological profile of EGFR mutations in lung adenocarcinoma in smokers and non-smokers exposed to wood smoke at INER.  Material and methods:  An observational, retrospective and cross-sectional study was conducted at INER, Mexico City. We included patients with a diagnosis of pulmonary adenocarcinoma in the period from June 2013 to December 2016. Qualitative variables (gender, occupation, biomass exposure, histological pattern of adenocarcinoma, degree of histological differentiation, clinical stage, presence of metastasis, Gene EGFR) and quantitative (age, smoking, exposure to wood smoke). The analysis was performed in terms of absolute and relative frequencies as well as measures of central tendency.  Results:  A total sample of 252 patients was analyzed, 58.33% female and 41.67%. Of the male sex. EGFR mutation was identified in 32.5%. It was found that the most frequently mutated exon in both sexes was the 19 with differences in histological pattern in relation to the exposition factor.  Conclusion:  The characterization of molecular profiles is an extremely useful tool in the presentation of therapeutic offers in non-small cell lung cancer. This is of interest since, like the histological pattern has a prognostic implication.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Adenocarcinoma pulmonar]]></kwd>
<kwd lng="es"><![CDATA[EGFR]]></kwd>
<kwd lng="es"><![CDATA[pronóstico]]></kwd>
<kwd lng="en"><![CDATA[Pulmonary adenocarcinoma]]></kwd>
<kwd lng="en"><![CDATA[EGFR]]></kwd>
<kwd lng="en"><![CDATA[prognosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Globocan</collab>
<source><![CDATA[Organización Mundial de la Salud]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duggan]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Altekruse]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Penberthy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship]]></article-title>
<source><![CDATA[Am J Surgical Pathol]]></source>
<year>2016</year>
<volume>40</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>e94-e102</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aldaco-Sarvide]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Pérez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cervantes-Sánchez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Torrecillas-Torres]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Erazo-V]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortalidad por cáncer en México 2000-2010: el recuento de los daños]]></article-title>
<source><![CDATA[Gaceta Mex Onc]]></source>
<year>2012</year>
<volume>11</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>371-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruíz-Godoy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rizo-Ríos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Cervantes]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Osornio-Vargas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Cuellar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Meneses-García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality due to lung cancer in Mexico]]></article-title>
<source><![CDATA[Lung Cancer]]></source>
<year>2007</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>184-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iniesta-Serrano]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinogénesis pulmonar]]></article-title>
<source><![CDATA[Rev Patol Respir]]></source>
<year>2007</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[de Castro]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores etiológicos del cáncer de pulmón: fumador activo, fumador pasivo, carcinógenos medioambientales y factores genéticos]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2007</year>
<volume>128</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>390-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Darby]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Deo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Silcocks]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Whitley]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Doll]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2000</year>
<volume>321</volume>
<numero>7257</numero>
<issue>7257</issue>
<page-range>323-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary adenocarcinomas: classification and reporting]]></article-title>
<source><![CDATA[Histopathology]]></source>
<year>2009</year>
<volume>54</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-27</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spiro]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Gould]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Colice]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory test, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition)]]></article-title>
<collab>American College of Chest Physicians</collab>
<source><![CDATA[Chest]]></source>
<year>2007</year>
<volume>132</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>149S-60S</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Vita]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer: Principles and practice of oncology]]></source>
<year>2010</year>
<edition>6</edition>
<publisher-loc><![CDATA[Boston ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott Williams &amp; Wilkins Publishers]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrieta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán-de Alba]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Alba-López]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consenso Nacional de Diagnóstico y Tratamiento del Cáncer de Pulmón de Células no Pequeñas. Consenso de Cáncer de Pulmón]]></article-title>
<source><![CDATA[Rev Invest Clin]]></source>
<year>2013</year>
<volume>65</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>s5-s84</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franco-Marina]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Villalba-Caloca]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La epidemia de cáncer pulmonar en México]]></article-title>
<source><![CDATA[Rev Inst Nal Enf Resp Mex]]></source>
<year>2001</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>207-14</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruano-Ravina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Villar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cribado de cáncer de pulmón con tomografía computarizada de baja dosis después del National Lung Screening Trial. El debate continúa abierto]]></article-title>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2013</year>
<volume>49</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>158-65</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Cepero]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Giordano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy]]></article-title>
<source><![CDATA[Mol Cancer]]></source>
<year>2010</year>
<volume>9</volume>
<page-range>75</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arora]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Scholar]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of tyrosine kinase inhibitors in cancer therapy]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>2005</year>
<volume>315</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>971-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wheatley-Price]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shepherd]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes]]></article-title>
<source><![CDATA[Curr Opin Oncol]]></source>
<year>2008</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>162-75</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Taron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reguart]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Isla]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2006</year>
<volume>12</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>7222-31</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Sordella]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>350</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2129-39</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yotsukura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yasuda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shigenobu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma]]></article-title>
<source><![CDATA[Lung Cancer]]></source>
<year>2017</year>
<volume>109</volume>
<page-range>45-51</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
